PT1052989E - Utilizacao do 2-amino-6-trifluorometoxibenzotiazole para a prevencao ou o tratamento das disfuncoes do cerebelo - Google Patents

Utilizacao do 2-amino-6-trifluorometoxibenzotiazole para a prevencao ou o tratamento das disfuncoes do cerebelo

Info

Publication number
PT1052989E
PT1052989E PT99901703T PT99901703T PT1052989E PT 1052989 E PT1052989 E PT 1052989E PT 99901703 T PT99901703 T PT 99901703T PT 99901703 T PT99901703 T PT 99901703T PT 1052989 E PT1052989 E PT 1052989E
Authority
PT
Portugal
Prior art keywords
prevention
treatment
trifluoromethoxybenzotizole
cerebellal
diseases
Prior art date
Application number
PT99901703T
Other languages
English (en)
Inventor
Assunta Imperato
Alain Boireau
Andrees Bohme
Thierry Canton
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PT1052989E publication Critical patent/PT1052989E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PT99901703T 1998-02-06 1999-02-03 Utilizacao do 2-amino-6-trifluorometoxibenzotiazole para a prevencao ou o tratamento das disfuncoes do cerebelo PT1052989E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9801402A FR2774592B1 (fr) 1998-02-06 1998-02-06 Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet

Publications (1)

Publication Number Publication Date
PT1052989E true PT1052989E (pt) 2003-12-31

Family

ID=9522673

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99901703T PT1052989E (pt) 1998-02-06 1999-02-03 Utilizacao do 2-amino-6-trifluorometoxibenzotiazole para a prevencao ou o tratamento das disfuncoes do cerebelo

Country Status (18)

Country Link
US (1) US6245791B1 (pt)
EP (1) EP1052989B1 (pt)
JP (1) JP5127092B2 (pt)
KR (1) KR100574378B1 (pt)
AT (1) ATE245982T1 (pt)
AU (1) AU761978B2 (pt)
CA (1) CA2319686C (pt)
DE (1) DE69909970T2 (pt)
DK (1) DK1052989T3 (pt)
EA (1) EA002676B1 (pt)
ES (1) ES2199541T3 (pt)
FR (1) FR2774592B1 (pt)
IL (2) IL137608A0 (pt)
NO (1) NO327819B1 (pt)
NZ (1) NZ506124A (pt)
PT (1) PT1052989E (pt)
WO (1) WO1999039710A1 (pt)
ZA (1) ZA99740B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60041365D1 (de) 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
MX2020012377A (es) * 2018-05-27 2021-04-12 Biohaven Therapeutics Ltd Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0374041B1 (fr) * 1988-12-15 1992-06-17 Rhone-Poulenc Sante Médicaments à base de dérivés de la benzothiazolamine-2, dérivés et leur préparation
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
FR2726271B1 (fr) * 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole

Also Published As

Publication number Publication date
DE69909970D1 (de) 2003-09-04
ATE245982T1 (de) 2003-08-15
US6245791B1 (en) 2001-06-12
CA2319686C (fr) 2009-06-23
KR20010040671A (ko) 2001-05-15
DE69909970T2 (de) 2004-05-27
ZA99740B (en) 1999-08-02
EP1052989A1 (fr) 2000-11-22
IL137608A (en) 2006-09-05
EA200000816A1 (ru) 2001-02-26
NO20003785L (no) 2000-07-24
ES2199541T3 (es) 2004-02-16
FR2774592A1 (fr) 1999-08-13
JP2002502819A (ja) 2002-01-29
DK1052989T3 (da) 2003-11-17
AU2171199A (en) 1999-08-23
EA002676B1 (ru) 2002-08-29
NZ506124A (en) 2003-07-25
AU761978B2 (en) 2003-06-12
FR2774592B1 (fr) 2000-03-17
CA2319686A1 (fr) 1999-08-12
NO20003785D0 (no) 2000-07-24
JP5127092B2 (ja) 2013-01-23
IL137608A0 (en) 2001-07-24
WO1999039710A1 (fr) 1999-08-12
NO327819B1 (no) 2009-09-28
EP1052989B1 (fr) 2003-07-30
KR100574378B1 (ko) 2006-04-26

Similar Documents

Publication Publication Date Title
DOP2002000429A (es) Imidazotriazinas
NO2012015I2 (no) Dapoxetine
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
CY1110448T1 (el) Ενωσεις ριλουζολης και λεβαντοπας για τη θεραπεια της ασθενειας του παρκινσον
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
RS51003B (sr) Derivat piridin-1-oksida i postupak za njegovu transformaciju u farmaceutski efikasna jedinjenja
AU2002222180A1 (en) The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity
PT1267915E (pt) Metodos para tratar doencas com proteina c activada
PT1052989E (pt) Utilizacao do 2-amino-6-trifluorometoxibenzotiazole para a prevencao ou o tratamento das disfuncoes do cerebelo
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
DE60004996D1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
ECSP003725A (es) Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina
UY26405A1 (es) Método para tratar el mal de parkinson a través de la administración de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina.
RU98112366A (ru) Препарат для лечения зудящих заболеваний
RU2002103977A (ru) Способ лечения острого гнойного пиелонефрита